CW May 2004
Volume 13Issue Number 5 May 2004 ISSN 10593802 New Drug Works in Synergy with Standard Anti-cancer TherapiesHistone deacetylase (HDAC) inhibitor represents a new class of targeted anti-cancer agents. Several structural classes of HDAC inhibitors are in clinical trials, including suberoylanilide hydroxamic acid (SAHA), a small molecule that alters the expression of a limited number of genes.
Go to Previous Page Go to Next Page Source & Additional Reading P. Marks, American Association for Cancer Research 95th annual meeting in Orlando, FL. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW May 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
